Literature DB >> 33429333

miR-193a-5p as a promising therapeutic candidate in colorectal cancer by reducing 5-FU and Oxaliplatin chemoresistance by targeting CXCR4.

Mohammad Reza Mohammad Hoseini Azar1, Hamed Aghazadeh2, Halgurd Nadhim Mohammed3, Mehdi Rezai Seghin Sara4, Arezoo Hosseini5, Navid Shomali6, Rozita Tamjidifar7, Saeed Tarzi7, Mahmoud Mansouri8, Sahar Pashaei Sarand9, Faroogh Marofi10, Morteza Akbari5, Huaxi Xu11, Siamak Sandoghchian Shotorbani12.   

Abstract

Colorectal cancer (CRC) is one of the most common causes of cancer-related deaths worldwide. The role of microRNAs (miRNAs/miRs) as small (19-25 nucleotides in length) non-coding RNA molecules that modify gene expression has been shown in several types of cancer. 5-Fluorouracil (5-FU) and oxaliplatin (Ox) are two common chemotherapeutic agents used to treat cancer. The present study aimed to evaluate the expression levels of miR-193a-5p in CRC, and its effect on the C-X-C Motif Chemokine Receptor 4 (CXCR4) target gene alone and in combination with chemotherapeutic drugs, to determine its possible role in chemoresistance. CRC tissues and adjacent non-cancerous tissue were obtained from 67 patients who had undergone surgery to determine the expression levels of miR-193a-5p and CXCR4. Subsequently, qPCR and Western blotting were performed to determine the effect of miR-193a-5p and chemotherapy drugs on CXCR4. َAlso, MTT assay, and flow cytometry was performed to determine their role in cell viability and apoptosis. Besides, the relationship between miR-193a-5p and CXCR4 with patients' clinical features was investigated. The results of the present study showed that miR-193a-5p was significantly downregulated, whereas CXCR4 was significantly upregulated in tumor tissues obtained from patients with CRC compared with the adjacent non-tumor healthy controls. In addition, the upregulation of miR-193-5p reduced the expression levels of CXCR4, particularly in combination with 5-FU and OX. Besides, using rescue experiments, the present study showed that miR-193a-5p replacement was able to suppress CXCR4-induced CRC cell proliferation by directly targeting CXCR4. Furthermore, there was a significant association between miR-193a-5p and CXCR4 with certain clinicopathological characteristics, particularly with metastasis-related features. These results suggest that miR-193a-5p serves a tumor-suppressive function in CRC and can directly target CXCR4 and decrease its mRNA and protein expression levels. Additionally, miR-193a-5p in combination with 5-FU and Ox potentiated reducing CXR4 expression, which may reveal its contribution to tumor chemoresistance. In conclusion, miR-193-5p may be applicable as a prognostic and diagnostic marker, and also serve as a therapeutic factor by reducing CXCR4 in combination with chemotherapeutic drugs.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  5-FU; CXCR4; Colorectal cancer; Oxaliplatin; miR-193a-5p

Mesh:

Substances:

Year:  2021        PMID: 33429333     DOI: 10.1016/j.intimp.2020.107355

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  8 in total

1.  Comprehensive bioinformatics analysis of functional molecules in colorectal cancer.

Authors:  Tao Meng; Zhangzhang Lan; Xiaoling Zhao; Li Niu; Chuan Chen; Wenyong Zhang
Journal:  J Gastrointest Oncol       Date:  2022-02

Review 2.  A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview.

Authors:  Ahmad Saburi; Mohammad Saeed Kahrizi; Navid Naghsh; Hasti Etemadi; Ahmet İlhan; Ali Adili; Shadi Ghoreishizadeh; Rozita Tamjidifar; Morteza Akbari; Gülinnaz Ercan
Journal:  J Ovarian Res       Date:  2022-07-07       Impact factor: 5.506

Review 3.  MicroRNAs and JAK/STAT3 signaling: A new promising therapeutic axis in blood cancers.

Authors:  Mehdi Sajjadi-Dokht; Talar Ahmad Merza Mohamad; Heshu Sulaiman Rahman; Marwah Suliman Maashi; Svetlana Danshina; Navid Shomali; Saeed Solali; Faroogh Marofi; Elham Zeinalzadeh; Morteza Akbari; Ali Adili; Ramin Aslaminabad; Majid Farshdousti Hagh; Mostafa Jarahian
Journal:  Genes Dis       Date:  2021-12-03

Review 4.  CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool.

Authors:  Roozbeh Moghaddar; Amirhossein Fakhre Yaseri; Sadegh Shojaei Baghini; Zhanna R Gardanova; Saeme Azizi Hassan Abadi; Burhan Abdullah Zaman; Ahmet İlhan; Navid Shomali; Ali Adili
Journal:  Cell Mol Biol Lett       Date:  2022-05-04       Impact factor: 8.702

Review 5.  Recent Advances in CXCL12/CXCR4 Antagonists and Nano-Based Drug Delivery Systems for Cancer Therapy.

Authors:  Ruogang Zhao; Jianhao Liu; Zhaohuan Li; Wenhui Zhang; Feng Wang; Bo Zhang
Journal:  Pharmaceutics       Date:  2022-07-25       Impact factor: 6.525

Review 6.  Potential of chimeric antigen receptor (CAR)-redirected immune cells in breast cancer therapies: Recent advances.

Authors:  Marzieh Nikoo; Mohammad Rudiansyah; Dmitry Olegovich Bokov; Nurlan T Jainakbaev; Wanich Suksatan; Mohammad Javed Ansari; Lakshmi Thangavelu; Supat Chupradit; Amir Zamani; Ali Adili; Navid Shomali; Morteza Akbari
Journal:  J Cell Mol Med       Date:  2022-06-28       Impact factor: 5.295

7.  Diagnostic Potential of microRNAs in Extracellular Vesicles Derived from Bronchoalveolar Lavage Fluid for Pneumonia-A Preliminary Report.

Authors:  Yinfang Sun; Ying Xian; Zhiqin Duan; Zhiping Wan; Jianwei Li; Yao Liao; Xiaogang Bi; Zhongdao Wu; Lifu Wang; Kouxing Zhang
Journal:  Cells       Date:  2022-09-22       Impact factor: 7.666

8.  Up-regulation of KISS1 as a novel target of Let-7i in melanoma serves as a potential suppressor of migration and proliferation in vitro.

Authors:  Haider A Alkafaji; Ahmed Raji; Heshu S Rahman; Angelina O Zekiy; Ali Adili; Mohammadmahdi Jalili; Tahereh Hojjatipour; Angel Cid-Arregui; Navid Shomali; Saeed Tarzi; Rozita Tamjidifar; Ramin Heshmati; Faroogh Marofi; Morteza Akbari; Ali Hasanzadeh; Mina Deljavanghodrati; Mostafa Jarahian; Siamak Sandoghchian Shotorbani
Journal:  J Cell Mol Med       Date:  2021-06-06       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.